Eric Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eric Yu has a total of 515 co-authors. Here are the top co-authors by number of shared publications:
- Ziv Gan-Or
Department of Human Genetics, McGill University, Montreal, QC, Canada
43 shared publications - Konstantin Senkevich
The Neuro (Montreal Neurological Institute-Hospital), McGill University
20 shared publications Farnaz Asayesh
The Neuro (Montreal Neurological Institute‐Hospital), McGill University Montréal Québec Canada
19 shared publicationsJennifer A. Ruskey
The Neuro (Montreal Neurological Institute‐Hospital), McGill University Montréal Québec Canada
15 shared publications- Uladzislau Rudakou
McGill University
13 shared publications - Guy Armand Rouleau
Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada
12 shared publications
Latest Publications
- Open Access
THE GENETIC LANDSCAPE OF HEREDITARY SPASTIC PARAPLEGIA IN CANADA
Background: Hereditary spastic paraplegia (HSP) comprises a heterogeneous group of neurodegenerative disorders characterized by progressive lower-extremity weakness and spasticity, with or without additional neurological symptoms. Objectives: To characterize the molecular genetic spectrum, inheritance patterns, molecular finding rate, and clinical characteristics of HSP within a multicenter Canadian cohort. Methods: We investigated 671 patients from 423 families who met clinical criteria for HSP identified through the Canadian HSP (CanHSP) registry from 7 medical centers across Canada. Patients were evaluated using known HSP and HSP mimic gene panels, whereas unsolved and more recent patients underwent whole-exome sequencing (WES). 435 individuals underwent gene-panel testing and 485 underwent WES. Copy-number variants (CNVs) were assessed using ExomeDepth, and candidate CNVs using multiplex ligation-dependent probe amplification (MLPA). Results: Molecular findings were identified in 426 of 671 individuals (63.5%): 351 (52.3%) had HSP-associated findings, 70 (10.4%) HSP-mimicking disorders, and five (0.7%) other molecular findings; 245 (36.5%) remained unresolved. Candidate variants were found in 80 relevant genes, 36 of which were HSP-associated genes. The most frequently implicated genes were SPAST (22.5%), SPG7 (5.7%), ATL1 (5.2%), SPG11 (3.6%), and SPG8 (3.3%). Phenotypically, SPAST , ATL1 , and SPG8 were predominantly associated with pure HSP, whereas SPG7 and SPG11 more often showed complicated phenotypes, with prominent cerebellar involvement in SPG7 and cognitive and developmental features in SPG11 . Conclusion: Patients in CanHSP present with genetic and phenotypic heterogeneity. Reanalysis and complementary approaches, including whole-genome, RNA, and long-read sequencing, may increase diagnostic yield.
Open AccessTHE GENETIC LANDSCAPE OF HEREDITARY SPASTIC PARAPLEGIA IN CANADA
Background: Hereditary spastic paraplegia (HSP) comprises a heterogeneous group of neurodegenerative disorders characterized by progressive lower-extremity weakness and spasticity, with or without additional neurological symptoms. Objectives: To characterize the molecular genetic spectrum, inheritance patterns, molecular finding rate, and clinical characteristics of HSP within a multicenter Canadian cohort. Methods: We investigated 671 patients from 423 families who met clinical criteria for HSP identified through the Canadian HSP (CanHSP) registry from 7 medical centers across Canada. Patients were evaluated using known HSP and HSP mimic gene panels, whereas unsolved and more recent patients underwent whole-exome sequencing (WES). 435 individuals underwent gene-panel testing and 485 underwent WES. Copy-number variants (CNVs) were assessed using ExomeDepth, and candidate CNVs using multiplex ligation-dependent probe amplification (MLPA). Results: Molecular findings were identified in 426 of 671 individuals (63.5%): 351 (52.3%) had HSP-associated findings, 70 (10.4%) HSP-mimicking disorders, and five (0.7%) other molecular findings; 245 (36.5%) remained unresolved. Candidate variants were found in 80 relevant genes, 36 of which were HSP-associated genes. The most frequently implicated genes were SPAST (22.5%), SPG7 (5.7%), ATL1 (5.2%), SPG11 (3.6%), and SPG8 (3.3%). Phenotypically, SPAST , ATL1 , and SPG8 were predominantly associated with pure HSP, whereas SPG7 and SPG11 more often showed complicated phenotypes, with prominent cerebellar involvement in SPG7 and cognitive and developmental features in SPG11 . Conclusion: Patients in CanHSP present with genetic and phenotypic heterogeneity. Reanalysis and complementary approaches, including whole-genome, RNA, and long-read sequencing, may increase diagnostic yield.
- Open Access
No evidence of association between PGK1 variants and Parkinson’s disease
Background: An X-linked levodopa-responsive parkinsonism-epilepsy syndrome has been associated with PGK1 , and the gene lies within the previously suspected PD locus PARK12 . Objective: To examine the association of common and rare PGK1 variants with PD. Methods: We analyzed common and rare variants from Accelerated Medicines Partnership - Parkinson’s Disease (AMP-PD) and UK Biobank (UKBB, total N=4,523 PD cases, 19,736 proxy cases, and 390,532 controls). To account for the X-linked location of PGK1 , we used sex-stratified, combined regression models and optimized sequence Kernel association (SKAT-O) tests, followed by meta-analysis using MetaSKAT. Results: We found no association between common or rare PGK1 variants and PD in sex-stratified or combined analyses, including after cross-cohort meta-analysis. Conclusion: Although we did not find evidence supporting an association between PGK1 and PD, very rare pathogenic PGK1 variants may still contribute to syndromic parkinsonism. Future research could explore larger datasets to further examine this potential association.
Open AccessNo evidence of association between PGK1 variants and Parkinson’s disease
Background: An X-linked levodopa-responsive parkinsonism-epilepsy syndrome has been associated with PGK1 , and the gene lies within the previously suspected PD locus PARK12 . Objective: To examine the association of common and rare PGK1 variants with PD. Methods: We analyzed common and rare variants from Accelerated Medicines Partnership - Parkinson’s Disease (AMP-PD) and UK Biobank (UKBB, total N=4,523 PD cases, 19,736 proxy cases, and 390,532 controls). To account for the X-linked location of PGK1 , we used sex-stratified, combined regression models and optimized sequence Kernel association (SKAT-O) tests, followed by meta-analysis using MetaSKAT. Results: We found no association between common or rare PGK1 variants and PD in sex-stratified or combined analyses, including after cross-cohort meta-analysis. Conclusion: Although we did not find evidence supporting an association between PGK1 and PD, very rare pathogenic PGK1 variants may still contribute to syndromic parkinsonism. Future research could explore larger datasets to further examine this potential association.
- Open Access
- 10 June 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (9) , 2349-2356
Rare‐Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease
Background: Lysosomal dysfunction is central to Parkinson's disease (PD) pathogenesis, with GBA1 representing the strongest established genetic risk factor. Numerous other genes involved in lysosomal sphingolipid, glycosphingolipid, and ceramide metabolism have been proposed as contributors to PD, highlighting the need for genetic analyses across these pathways. Objectives: The aim was to evaluate the contribution of rare variants across lysosomal genes to PD risk. Methods: We analyzed rare variants (minor allele frequency ≤0.01) across 36 lysosomal genes in 8267 individuals with PD and 68,208 controls, including 793 early‐onset PD (≤50 years) cases. Targeted sequencing was performed in four cohorts at McGill University (3456 cases and 2664 controls) and combined with whole‐genome sequencing data from the United Kingdom (UK) Biobank (2848 cases, 62,451 controls) and the Accelerating Medicines Partnership‐PD cohort (1963 cases, 3093 controls). Associations were tested using Sequence Kernel Association Test‐Optimal across variant classes (rare variants, nonsynonymous, loss‐of‐function, and predicted damaging variants with combined annotation‐dependent depletion score >20), followed by meta‐analysis across cohorts. Domain‐level analyses were performed for variants located within protein domains. False discovery rate (FDR) correction was applied. Results: Meta‐analysis identified a significant association between rare variants in ST3GAL3 and Parkinson's disease (Pfdr = 0.04). Domain‐based analyses showed enrichment of nonsynonymous variants within the β‐acetyl‐hexosaminidase–like domain of HEXA ( P = 8.0 × 10 −4 ), although this signal did not survive correction (Pfdr = 0.154). In early‐onset PD, domain‐based analyses identified significant associations in NAGLU (Pfdr = 7.3 × 10 −6 ) and ST3GAL5 (Pfdr = 0.03). Conclusions: Rare variants across multiple lysosomal pathways, particularly those related to sialylation, ganglioside metabolism, ceramide biology, and lysosomal proteolysis, may contribute to PD susceptibility beyond GBA1 , highlighting pathways for future replication and investigation. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 10 June 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (9) , 2349-2356
Open AccessRare‐Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease
Background: Lysosomal dysfunction is central to Parkinson's disease (PD) pathogenesis, with GBA1 representing the strongest established genetic risk factor. Numerous other genes involved in lysosomal sphingolipid, glycosphingolipid, and ceramide metabolism have been proposed as contributors to PD, highlighting the need for genetic analyses across these pathways. Objectives: The aim was to evaluate the contribution of rare variants across lysosomal genes to PD risk. Methods: We analyzed rare variants (minor allele frequency ≤0.01) across 36 lysosomal genes in 8267 individuals with PD and 68,208 controls, including 793 early‐onset PD (≤50 years) cases. Targeted sequencing was performed in four cohorts at McGill University (3456 cases and 2664 controls) and combined with whole‐genome sequencing data from the United Kingdom (UK) Biobank (2848 cases, 62,451 controls) and the Accelerating Medicines Partnership‐PD cohort (1963 cases, 3093 controls). Associations were tested using Sequence Kernel Association Test‐Optimal across variant classes (rare variants, nonsynonymous, loss‐of‐function, and predicted damaging variants with combined annotation‐dependent depletion score >20), followed by meta‐analysis across cohorts. Domain‐level analyses were performed for variants located within protein domains. False discovery rate (FDR) correction was applied. Results: Meta‐analysis identified a significant association between rare variants in ST3GAL3 and Parkinson's disease (Pfdr = 0.04). Domain‐based analyses showed enrichment of nonsynonymous variants within the β‐acetyl‐hexosaminidase–like domain of HEXA ( P = 8.0 × 10 −4 ), although this signal did not survive correction (Pfdr = 0.154). In early‐onset PD, domain‐based analyses identified significant associations in NAGLU (Pfdr = 7.3 × 10 −6 ) and ST3GAL5 (Pfdr = 0.03). Conclusions: Rare variants across multiple lysosomal pathways, particularly those related to sialylation, ganglioside metabolism, ceramide biology, and lysosomal proteolysis, may contribute to PD susceptibility beyond GBA1 , highlighting pathways for future replication and investigation. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 22 May 2026
- Published by Wiley in Movement Disorders
The GBA1 p. E427K (p. E388K ) Variant Is a Risk Factor for Synucleinopathies: A Meta‐Analysis
Background: Variants in GBA1 are important genetic risk factors for synucleinopathies, including Parkinson's disease (PD). Although several GBA1 variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear. Objective: The aim was to determine whether the GBA1 p.E427K variant is associated with risk of synucleinopathies. Methods: We performed a meta‐analysis of case–control studies reporting the frequency of GBA1 p.E427K (p.E388K) in PD and related synucleinopathies. Data were obtained from published studies, open‐access resources, and large cohorts, including in‐house datasets. Odds ratios (OR) were calculated for each cohort and pooled using a random‐effects model. Results: Across 67,221 patients and 123,832 controls, GBA1 p.E427K was associated with increased disease risk (pooled OR = 1.94, 95% confidence interval 1.33–2.84, P = 0.0007). Enzymatic data showed reduced glucocerebrosidase activity in carriers. Conclusions: The GBA1 p.E427K variant is a risk factor for synucleinopathies and should be considered in genetic studies and clinical trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 22 May 2026
- Published by Wiley in Movement Disorders
Open AccessThe GBA1 p. E427K (p. E388K ) Variant Is a Risk Factor for Synucleinopathies: A Meta‐Analysis
Background: Variants in GBA1 are important genetic risk factors for synucleinopathies, including Parkinson's disease (PD). Although several GBA1 variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear. Objective: The aim was to determine whether the GBA1 p.E427K variant is associated with risk of synucleinopathies. Methods: We performed a meta‐analysis of case–control studies reporting the frequency of GBA1 p.E427K (p.E388K) in PD and related synucleinopathies. Data were obtained from published studies, open‐access resources, and large cohorts, including in‐house datasets. Odds ratios (OR) were calculated for each cohort and pooled using a random‐effects model. Results: Across 67,221 patients and 123,832 controls, GBA1 p.E427K was associated with increased disease risk (pooled OR = 1.94, 95% confidence interval 1.33–2.84, P = 0.0007). Enzymatic data showed reduced glucocerebrosidase activity in carriers. Conclusions: The GBA1 p.E427K variant is a risk factor for synucleinopathies and should be considered in genetic studies and clinical trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
The GBA1 p.E427K (p.E388K) Variant is a Risk Factor for Synucleinopathies: A Meta-Analysis
Background: Variants in GBA1 are important genetic risk factors for synucleinopathies, including Parkinson’s disease (PD). While several GBA1 variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear. Objective To determine whether the GBA1 p.E427K variant is associated with risk of synucleinopathies. Methods: We performed a meta-analysis of case-control studies reporting the frequency of GBA1 p.E427K (p.E388K) in PD and related synucleinopathies. Data were obtained from published studies, open-access resources, and large cohorts, including in-house datasets. Odds ratios (ORs) were calculated for each cohort and pooled using a random-effects model. Results: Across 67,484 patients and 124,079 controls, GBA1 p.E427K was associated with increased disease risk (pooled OR = 1.87, 95% CI 1.28–2.72, P = 0.001). Enzymatic data showed reduced glucocerebrosidase activity in carriers. Conclusions: The GBA1 p.E427K variant is a risk factor for synucleinopathies and should be considered in genetic studies and clinical trials.
Open AccessThe GBA1 p.E427K (p.E388K) Variant is a Risk Factor for Synucleinopathies: A Meta-Analysis
Background: Variants in GBA1 are important genetic risk factors for synucleinopathies, including Parkinson’s disease (PD). While several GBA1 variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear. Objective To determine whether the GBA1 p.E427K variant is associated with risk of synucleinopathies. Methods: We performed a meta-analysis of case-control studies reporting the frequency of GBA1 p.E427K (p.E388K) in PD and related synucleinopathies. Data were obtained from published studies, open-access resources, and large cohorts, including in-house datasets. Odds ratios (ORs) were calculated for each cohort and pooled using a random-effects model. Results: Across 67,484 patients and 124,079 controls, GBA1 p.E427K was associated with increased disease risk (pooled OR = 1.87, 95% CI 1.28–2.72, P = 0.001). Enzymatic data showed reduced glucocerebrosidase activity in carriers. Conclusions: The GBA1 p.E427K variant is a risk factor for synucleinopathies and should be considered in genetic studies and clinical trials.
- Open Access
Brain size links neurodevelopment to neurodegeneration in Parkinson's disease
Genetic studies have advanced our understanding of Parkinson's disease (PD) pathogenesis, establishing a role for autophagy and lysosomal dysfunction. However, how genetic risk translates into neuronal vulnerability remains mostly unknown. Using recent genome-wide association studies and neuroimaging data from UK Biobank, we show that higher polygenic risk score of PD correlates with greater cortical surface area, white matter fractional anisotropy and subcortical volumes. Mendelian randomization supports a causal relation from increased brain size to PD, and cortical regions showing the greatest polygenic expansion in surface area show the greatest atrophy in PD. Lifespan gene expression and pathway-specific analyses identify autophagy-lysosomal and neurodevelopmental pathways as separate mechanisms of vulnerability. We show that a portion of PD susceptibility originates from neurodevelopmental processes that regulate neuronal proliferation. Genetically-determined increases in brain size confer vulnerability to PD in later life, supporting the existence of shared neurobiological pathways between brain development and neurodegeneration.
Open AccessBrain size links neurodevelopment to neurodegeneration in Parkinson's disease
Genetic studies have advanced our understanding of Parkinson's disease (PD) pathogenesis, establishing a role for autophagy and lysosomal dysfunction. However, how genetic risk translates into neuronal vulnerability remains mostly unknown. Using recent genome-wide association studies and neuroimaging data from UK Biobank, we show that higher polygenic risk score of PD correlates with greater cortical surface area, white matter fractional anisotropy and subcortical volumes. Mendelian randomization supports a causal relation from increased brain size to PD, and cortical regions showing the greatest polygenic expansion in surface area show the greatest atrophy in PD. Lifespan gene expression and pathway-specific analyses identify autophagy-lysosomal and neurodevelopmental pathways as separate mechanisms of vulnerability. We show that a portion of PD susceptibility originates from neurodevelopmental processes that regulate neuronal proliferation. Genetically-determined increases in brain size confer vulnerability to PD in later life, supporting the existence of shared neurobiological pathways between brain development and neurodegeneration.
- Open Access
Investigating the Effect of Cardiovascular Exercise on Brain-Derived Neurotrophic Factor in Early Subacute Stroke
: Background.: Following stroke, a growth-promoting response resulting in heightened neuroplasticity occurs during the early subacute stages of recovery, a period during which the brain may be more responsive to therapeutical interventions. Given its central role in regulating neuroplastic processes and brain repair in animal models, brain-derived neurotrophic factor (BDNF) has been investigated as a potential biomarker for stroke recovery in humans, with interventions upregulating it holding therapeutical potential. Cardiovascular exercise (CE) has been recommended for stroke rehabilitation, partly due to its potential to induce neural adaptations, including upregulation of BDNF. Objectives.: To examine the effects of CE on BDNF in individuals at early subacute stages of recovery. Methods.: 76 participants within 3 months of first-ever ischemic stroke were randomly assigned to eight weeks of either CE plus standard care or standard care alone. To measure the chronic and acute responses to exercise in serum BDNF levels, blood samples were collected before and immediately after a graded exercise test conducted at baseline, four and eight weeks. The potential role of the BDNF Val66Met polymorphism in modulating the BDNF response to CE was also explored. Results.: Despite significant increases in cardiorespiratory fitness, CE did not induce any significant chronic or acute changes in BDNF concentration. Similarly, the BDNF response to CE was not modulated by the Val66Met polymorphism or associated with changes in cardiorespiratory fitness and clinical outcomes. Conclusions.: These findings indicate limited effects of CE in modulating circulating BDNF in subacute stages of stroke recovery. Trial Registration: Exercise and Genotype in Sub-acute Stroke: https://clinicaltrials.gov/study/NCT05076747
Open AccessInvestigating the Effect of Cardiovascular Exercise on Brain-Derived Neurotrophic Factor in Early Subacute Stroke
: Background.: Following stroke, a growth-promoting response resulting in heightened neuroplasticity occurs during the early subacute stages of recovery, a period during which the brain may be more responsive to therapeutical interventions. Given its central role in regulating neuroplastic processes and brain repair in animal models, brain-derived neurotrophic factor (BDNF) has been investigated as a potential biomarker for stroke recovery in humans, with interventions upregulating it holding therapeutical potential. Cardiovascular exercise (CE) has been recommended for stroke rehabilitation, partly due to its potential to induce neural adaptations, including upregulation of BDNF. Objectives.: To examine the effects of CE on BDNF in individuals at early subacute stages of recovery. Methods.: 76 participants within 3 months of first-ever ischemic stroke were randomly assigned to eight weeks of either CE plus standard care or standard care alone. To measure the chronic and acute responses to exercise in serum BDNF levels, blood samples were collected before and immediately after a graded exercise test conducted at baseline, four and eight weeks. The potential role of the BDNF Val66Met polymorphism in modulating the BDNF response to CE was also explored. Results.: Despite significant increases in cardiorespiratory fitness, CE did not induce any significant chronic or acute changes in BDNF concentration. Similarly, the BDNF response to CE was not modulated by the Val66Met polymorphism or associated with changes in cardiorespiratory fitness and clinical outcomes. Conclusions.: These findings indicate limited effects of CE in modulating circulating BDNF in subacute stages of stroke recovery. Trial Registration: Exercise and Genotype in Sub-acute Stroke: https://clinicaltrials.gov/study/NCT05076747
- Open Access
- 1 March 2025
- Published by Wiley in Annals of Neurology
- Vol. 97 (5) , 873-878
Plasma Glucosylceramide Levels Are Regulated by ATP10D and Are Not Involved in Parkinson's Disease Pathogenesis
GBA1 variants and decreased glucocerebrosidase activity are implicated in Parkinson's disease (PD). We investigated the hypothesis that increased levels of glucosylceramide (GlcCer), a main substrate of glucocerebrosidase, are involved in PD pathogenesis. Using multiple genetic methods, we show that ATPase phospholipid transporting 10D (ATP10D), not GBA1, is the main regulator of plasma GlcCer levels, yet it is not involved in PD pathogenesis. Plasma GlcCer levels were associated with PD, but not in a causative manner, and are not predictive of disease status. These results argue against targeting GlcCer in GBA1‐PD, and underscore the need to explore alternative mechanisms and biomarkers for PD. ANN NEUROL 2025;97:873–878
- 1 March 2025
- Published by Wiley in Annals of Neurology
- Vol. 97 (5) , 873-878
Open AccessPlasma Glucosylceramide Levels Are Regulated by ATP10D and Are Not Involved in Parkinson's Disease Pathogenesis
GBA1 variants and decreased glucocerebrosidase activity are implicated in Parkinson's disease (PD). We investigated the hypothesis that increased levels of glucosylceramide (GlcCer), a main substrate of glucocerebrosidase, are involved in PD pathogenesis. Using multiple genetic methods, we show that ATPase phospholipid transporting 10D (ATP10D), not GBA1, is the main regulator of plasma GlcCer levels, yet it is not involved in PD pathogenesis. Plasma GlcCer levels were associated with PD, but not in a causative manner, and are not predictive of disease status. These results argue against targeting GlcCer in GBA1‐PD, and underscore the need to explore alternative mechanisms and biomarkers for PD. ANN NEUROL 2025;97:873–878
- Open Access
Associations between epilepsy-related polygenic risk and brain morphology in childhood
A bstract: Temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) is associated with a complex genetic architecture, but the translation from genetic risk factors to brain vulnerability remains unclear. Here, we examined associations between epilepsy-related polygenic risk scores for HS (PRS-HS) and brain structure in a large sample of neurotypical children, and correlated these signatures with case-control findings in in multicentric cohorts of patients with TLE-HS. Imaging-genetic analyses revealed PRS-related cortical thinning in temporo-parietal and fronto-central regions, strongly anchored to distinct functional and structural network epicentres. Compared to disease-related effects derived from epilepsy case-control cohorts, structural correlates of PRS-HS mirrored atrophy and epicentre patterns in patients with TLE-HS. By identifying a potential pathway between genetic vulnerability and disease mechanisms, our findings provide new insights into the genetic underpinnings of structural alterations in TLE-HS and highlight potential imaging-genetic biomarkers for early risk stratification and personalized interventions.
Open AccessAssociations between epilepsy-related polygenic risk and brain morphology in childhood
A bstract: Temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) is associated with a complex genetic architecture, but the translation from genetic risk factors to brain vulnerability remains unclear. Here, we examined associations between epilepsy-related polygenic risk scores for HS (PRS-HS) and brain structure in a large sample of neurotypical children, and correlated these signatures with case-control findings in in multicentric cohorts of patients with TLE-HS. Imaging-genetic analyses revealed PRS-related cortical thinning in temporo-parietal and fronto-central regions, strongly anchored to distinct functional and structural network epicentres. Compared to disease-related effects derived from epilepsy case-control cohorts, structural correlates of PRS-HS mirrored atrophy and epicentre patterns in patients with TLE-HS. By identifying a potential pathway between genetic vulnerability and disease mechanisms, our findings provide new insights into the genetic underpinnings of structural alterations in TLE-HS and highlight potential imaging-genetic biomarkers for early risk stratification and personalized interventions.
- Open Access
- 25 October 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-5
Are rare heterozygous SYNJ1 variants associated with Parkinson’s disease?
Previous studies have established that rare biallelic SYNJ1 mutations cause autosomal recessive parkinsonism and Parkinson’s disease (PD). We analyzed 8165 PD cases, 818 early-onset-PD (EOPD, < 50 years) and 70,363 controls. Burden meta-analysis revealed an association between rare nonsynonymous variants and variants with high Combined Annotation-Dependent Depletion score (> 20) in the Sac1 SYNJ1 domain and PD (Pfdr = 0.040). A meta-analysis of EOPD patients demonstrated an association between all rare heterozygous SYNJ1 variants and PD (Pfdr = 0.029).
- 25 October 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-5
Open AccessAre rare heterozygous SYNJ1 variants associated with Parkinson’s disease?
Previous studies have established that rare biallelic SYNJ1 mutations cause autosomal recessive parkinsonism and Parkinson’s disease (PD). We analyzed 8165 PD cases, 818 early-onset-PD (EOPD, < 50 years) and 70,363 controls. Burden meta-analysis revealed an association between rare nonsynonymous variants and variants with high Combined Annotation-Dependent Depletion score (> 20) in the Sac1 SYNJ1 domain and PD (Pfdr = 0.040). A meta-analysis of EOPD patients demonstrated an association between all rare heterozygous SYNJ1 variants and PD (Pfdr = 0.029).